Skip to main content

Mircera Disease Interactions

There are 4 disease interactions with Mircera (epoetin beta-methoxy polyethylene glycol).

Major

Erythropoiesis stimulating agents (applies to Mircera) seizures

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The use of erythropoiesis stimulating agents increases the risk of seizures in patients with chronic renal failure. Seizure development may be related to the rate of rise in hematocrit, which is also associated with blood pressure elevations. It is recommended to monitor patients closely for the development of premonitory neurologic symptoms during the first several months after the administration of these agents. Patients with epilepsy or predisposed to seizures should be monitored closely for blood pressure changes and neurologic symptoms during therapy with these agents.

Switch to professional interaction data

Major

Erythropoiesis-stimulating agents (applies to Mircera) hemodialysis

Major Potential Hazard, Moderate plausibility.

The increase in hematocrit and decrease in plasma volume associated with erythropoiesis-stimulating agents therapy may, theoretically, affect dialysis efficiency. Patients may require adjustments in their dialysis prescription after initiation of erythropoiesis stimulating agents. During hemodialysis, patients may require increased anticoagulation with heparin to prevent clotting.

Switch to professional interaction data

Major

Erythropoiesis-stimulating agents (applies to Mircera) hypertension

Major Potential Hazard, Moderate plausibility.

The use of erythropoiesis-stimulating agents is contraindicated in patients with uncontrolled hypertension. These agents may cause blood pressure to rise. Hypertensive encephalopathy and seizures have been observed in patients with chronic renal failure treated with these agents. Blood pressure should be adequately controlled prior to initiation of therapy, and monitored closely during treatment. Aggressive antihypertensive measures may be necessary, particularly early on in treatment when the hematocrit is increasing. It is recommended to reduce or withhold the use of these agents if blood pressure becomes difficult to control.

Switch to professional interaction data

Major

Erythropoiesis-stimulating agents (applies to Mircera) pure red cell aplasia

Major Potential Hazard, Moderate plausibility.

The use of erythropoiesis-stimulating agents is contraindicated in patients that develop pure red cell aplasia that begins after treatment with erythropoietin protein drugs.

Switch to professional interaction data

Mircera drug interactions

There are 23 drug interactions with Mircera (epoetin beta-methoxy polyethylene glycol).

Mircera alcohol/food interactions

There is 1 alcohol/food interaction with Mircera (epoetin beta-methoxy polyethylene glycol).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer